Alignment Healthcare (ALHC) Projected to Post Quarterly Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC) is projected to announce its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Alignment Healthcare to announce earnings of $0.13 per share and revenue of $1.3099 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 5:00 PM ET.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, April 30th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.22 billion. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The firm’s revenue was up 33.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) EPS. On average, analysts expect Alignment Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alignment Healthcare Stock Down 1.3%

Alignment Healthcare stock opened at $18.43 on Wednesday. The stock has a market cap of $3.81 billion, a PE ratio of 204.78, a price-to-earnings-growth ratio of 2.52 and a beta of 1.05. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. Alignment Healthcare has a one year low of $11.73 and a one year high of $25.12. The stock has a fifty day moving average of $19.66 and a 200 day moving average of $19.83.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Analysts maintain an average “Moderate Buy” recommendation, indicating that Wall Street sentiment remains supportive despite the recent controversy. Alignment Healthcare analyst recommendation
• Neutral Sentiment: Kaplan Fox, Pomerantz, Howard G. Smith, Frank R. Cruz, Hagens Berman and other firms have announced investor investigations or encouraged shareholders with losses to contact them. These announcements are largely attorney solicitations and do not establish that Alignment Healthcare violated securities laws. Kaplan Fox investigation
• Negative Sentiment: The investigations follow a whistleblower lawsuit alleging that Alignment Healthcare misclassified approximately $8 million to $10 million of operating expenses as capital expenditures, potentially inflating EBITDA and other financial results. The former executive also reportedly alleges retaliation after raising the accounting concerns internally. Howard G. Smith investigation
• Negative Sentiment: The allegations raise risks of financial restatements, regulatory scrutiny, litigation expenses and weaker investor confidence. News of the whistleblower lawsuit previously contributed to a sharp decline in ALHC shares, and the wave of investigations is extending that overhang. Hagens Berman investigation

Wall Street Analyst Weigh In

ALHC has been the topic of a number of research reports. UBS Group reissued a “neutral” rating on shares of Alignment Healthcare in a report on Wednesday, July 8th. Weiss Ratings raised shares of Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Barclays decreased their price target on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Raymond James Financial set a $22.00 price target on shares of Alignment Healthcare in a research note on Thursday, May 7th. Finally, Wolfe Research initiated coverage on shares of Alignment Healthcare in a research report on Friday, April 17th. They set an “outperform” rating and a $24.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Alignment Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $24.30.

Insiders Place Their Bets

In other news, insider Hyong Kim sold 35,951 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $19.86, for a total value of $713,986.86. Following the transaction, the insider directly owned 331,750 shares in the company, valued at $6,588,555. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John E. Kao sold 298,000 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $19.86, for a total value of $5,918,280.00. Following the completion of the transaction, the chief executive officer directly owned 1,088,766 shares of the company’s stock, valued at approximately $21,622,892.76. This trade represents a 21.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,039,951 shares of company stock worth $19,976,967 in the last three months. 5.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its holdings in Alignment Healthcare by 26.9% during the 4th quarter. Wellington Management Group LLP now owns 14,070,893 shares of the company’s stock valued at $277,900,000 after buying an additional 2,981,166 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Alignment Healthcare by 0.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after buying an additional 79,268 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Alignment Healthcare by 38.9% in the fourth quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after buying an additional 1,735,962 shares in the last quarter. 8 Knots Management LLC lifted its holdings in shares of Alignment Healthcare by 6.4% in the second quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock worth $70,222,000 after buying an additional 300,409 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Alignment Healthcare by 14.3% during the fourth quarter. State Street Corp now owns 3,668,602 shares of the company’s stock worth $72,455,000 after acquiring an additional 460,154 shares during the last quarter. 86.19% of the stock is owned by hedge funds and other institutional investors.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.